Introduction
Tuberculosis (TB) is a dangerous disease caused by species found in Mycobacterium tuberculosis complex that includes M. tuberculosis (Mtb). In the year 2012, an estimated 8.6 million people developed TB and 1.3 million died from the disease 1 (including 320 000 deaths among HIV-positive people). The number of TB deaths is unacceptably large given that most are preventable. Nearly 20 years after the WHO declaration of TB as a global public health emergency. So the novel therapeutics is necessary to treat both drug-susceptible TB and progressively common drug resistant strains.
Pyrimido [1,2-a] benzimidazoles were the class of fused cyclic bridgehead nitrogen compounds represent a pharmaceutically important class of compound because of their diverse range of biological activities as antineoplastic, 2 anti-tumor, 3 cytotoxic agents, 4, 5 antiulcer and imunotropic compounds. 6, 7 Coumarin substituted dihydrobenzo [4, 5] imidazo[1,2-a]pyrimidin-4-one was found to be the most potent cytotoxic compound (88%) against Dalton's Ascitic Lymphoma cell, 8 1-[(2E)-3-phenylprop-2-enoyl]-1H-benzimidazole was found to be anti-tubercular activity against Mycobacterium tuberculosis H37Rv. 9 As sulfonamides (SO2-NH) have great importance in medicinal chemistry, with various biological activities such as HIV protease inhibitors, 10 anti-tumor, 11 carbonic anhydrase (CA) inhibitors, 12 anti-inflammatory, 13 anti-cancer activities, 14, 15 antiviral, 16, 17 antibiotics. 18 Recently shah et.al reviewed the medicinal chemistry of sulfonamide derivatives. 19 Considering the biological significance of nitrogen containing heterocycles like pyrimidones, sulphonamide moieties, we here designed and synthesised phenyl sulfonyl substituted pyrimido [1, 2- As depicted in Scheme 1, the key intermediate 1 was prepared as reported 20 and 10-Phenyl sulfonyl-2-alkyl-4, 10 dihydrobenzo [4, 5] imidazo [1,2-a]pyrimidin-4-ones (3a-3i) were obtained by condensation of phenyl sulfonyl chloride (2) with pyrimido [1, 2-a] benzimidazolones (1a-1c) using K2CO3 as a mild catalyst in solvent (acetonitrile and [bmim]Cl) at room temperature for 18-24 min (table 1). All the synthesized compounds 3a-3i was purified by recrystallization using ethanol solvent. The structures of target compounds were characterized by IR, 1 H NMR, 13 C NMR, ESI-MS techniques and single crystal. The antituberculosis activity of all the newly synthesized compounds (3a-3i) was investigated against mycobacterium tuberculosis H37Rv strain by microplate alamar blue assay (MABA) method and the corresponding results are shown in table 2. As evident from the table, all the newly synthesized compounds exhibited anti-tubercular activity with moderate values, with a minimum inhibitory concentration (MIC) of 50.0 µg mL -1 . The MIC is defined as the lowest concentration (µg mL -1 ) of the compound required to inhibit the bacterial growth, completely. All compounds showed moderate in vitro activity against H37Rv strain as compared to pyrazinamide and streptomycin (MIC = 3.12 and 6.25 µg mL -1 ) respectively. Table 2 . Anti-tubercular activities and log P measurements of 10-Phenyl sulfonyl-2-alkyl/aryl-4, 10 dihydrobenzo [4, 5] Fig. 2 shows the ORTEP view of the molecule with atomic labeling and the displacement ellipsoids of non-hydrogen drawn at 50% probability level. hydrogen atoms drawn at the 50% probability level
Conclusions
In summary, in order to develop the potent anti-tubercular agents, we developed the design and synthesis of 10-Phenyl sulfonyl-2-alkyl-4, 10 dihydrobenzo [4, 5] imidazo [1, 2-a] pyrimidin-4-ones (3) and evaluated for their in vitro anti-tuberculosis activities against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay (MABA) method.
Experimental

Materials and Methods
All solvents and reagents were commercial grade and used without further purification unless otherwise stated. Melting points were uncorrected. Nuclear magnetic resonance spectra were obtained on a Bruker AMX spectrophotometer in CDCI3 at 300 MHz. Chemical shifts were obtained in parts per million and were measured using tetramethylsilane (TMS) as reference. IR spectra were recorded on a Shimadzu FT-IR-8400S spectrophotometer using KBr pellets and are reported as wave numbers (cm -1 ). Single Crystal X-ray analysis was done on Oxford Diffraction Xcalibur Eos Gemini diffractometer, complete crystal structure results as a CIF file including bond lengths, angles, and atomic coordinates are deposited in the Cambridge Crystallographic Data Center (CCDC). 
Single crystal X-ray data collection.
CrysAlis PRO (Oxford Diffraction
,): δ = 24.3, 56.2, 105.5, 113.4, 116.4, 123.5, 125.0, 126.7, 129.5, 146.1, 151.8, 152.6, 159.4, 164.0. MS(EI) m/z 421.2 (M+Na).
Crystallographic analysis of the compounds 3f
The compound 3f was crystallized using ethanol by slow evaporation method. The compound 3f (Fig. 3) . The Crystal data and other parameters are given in the Table 3 . 
